目的 探討沙利度胺片聯(lián)合鹽酸多西環(huán)素片治療Ⅰ、Ⅱ型玫瑰痤瘡的臨床療效。方法 選擇2023年1月—2023年6月在皖南醫(yī)學院第一附屬醫(yī)院（弋磯山醫(yī)院）、南陽市中心醫(yī)院皮膚科門診就診的80例Ⅰ、Ⅱ型玫瑰痤瘡患者作為研究對象，所有患者按照隨機數(shù)字表法隨機分為對照組和治療組，每組40例。對照組口服鹽酸多西環(huán)素片，0.1 g/次，2次/d；治療組在對照組治療的基礎上口服沙利度胺片，50 mg/次，2次/d。兩組均連續(xù)治療2個月。比較兩組的臨床療效、面部癥狀改善情況和血清因子水平。結果 治療后，對照組和治療組總有效率分別為70.00%、90.00%，組間比較差異顯著（P＜0.05）。治療后，兩組患者紅斑和毛細血管擴張、丘疹、膿皰、瘙癢評分均顯著降低（P＜0.05），且治療組患者紅斑和毛細血管擴張、丘疹、膿皰、瘙癢評分低于對照組（P＜0.05）。治療后，兩組患者血清中白細胞介素-17（IL-17）、腫瘤壞死因子-α（TNF-α）和血管內皮生長因子（VEGF）水平均顯著降低（P＜0.05），且治療組血清中IL-17、TNF-α和VEGF水平低于對照組（P＜0.05））。結論 沙利度胺片聯(lián)合鹽酸多西環(huán)素片治療Ⅰ、Ⅱ型玫瑰痤瘡有效性較高，能明顯改善患者的面部癥狀，緩解機體的炎癥狀態(tài)。

Objective To investigate the clinical efficacy of Thalidomide Tablets combined with doxycycline in treatment of type I and type II rosacea. Methods A total of 80 patients with type I, II rosacea in Nanyang Central Hospital and The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital) were included from January 2023 and June 2023 and divided into control group (40 cases) and treatment group (40 cases), respectively. Patients of the control group were po administered with Doxycycline Hyclate Tablets, 0.1 g/time, twice daily. Patients of the treatment group were po administered with Thalidomide Tablets on the basis of the control group, 50 mg/time, twice daily. Patients of both groups were treated for 2 months. The clinical efficacy, facial symptoms, and serum factor levels were compared between two groups. Results After treatment, the total effective rate of control group and treatment group was 70.00% and 90.00%, respectively, with significant difference between groups (P < 0.05). The scores of facial erythema, telangiectasia, papules, pustules, and pruritus in two groups after treatment were significantly decreased (P < 0.05). Compared with the control group, the scores of facial erythema, telangiectasia, papules, pustules, and pruritus in the treatment group were significantly decreased, with a statistical significance (P < 0.05). After treatment, the serum levels of IL-17, TNF-α, and VEGF in two groups were significantly decreased, and the serum levels of IL-17, TNF-α, and VEGF in treatment group were significantly lower than those in the control group, with a statistical significance (P < 0.05). Conclusion Thalidomide Tablets combined with Doxycycline Hyclate Tablets has a significant clinical efficacy in treatment of type I, II rosacea, and can obviously improve the facial symptoms of patients, and relieve the inflammatory state of the body.

R986

安徽省自然科學基金立項項目(2308085QH269)